ARCHIVES

FDA Approves Gleevec For First Line Rx Of CML

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

NIH grant success rate drops to under 20 percent after 2011 budget cuts

May 13, 2011

Three Studies Demonstrate Oncotype DX Test Effectiveness

March 30, 2012

Three Nurse Awards Made In Self Care

September 30, 1988

Immune Therapy Possible For Metastatic Breast Cancer

September 24, 2004

Hawking Hearings Turn Up Difference Between Management, Staff At FDA

November 20, 1981

Talbot, Schein Ask Weickar for 41.3 Billion for NCI

May 6, 1983